Recursion gives guidance on seven clinical readouts within ~18 months and Bayer LOWE partnership

RECURSION PHARMACEUTICALS, INC.

Topline Phase 2 data for REC-994 (CCM) in Sep 2024; prelim Phase 2 data for REC-2282 (NF2) in Q4 2024.
REC-3964 (C. diff) Phase 2 start Q4 2024; RBM39 IND Q3 2024; Target Epsilon IND early 2025.
Bayer first beta-user of LOWE platform; joint oncology project towards Lead Series nomination; 25 data packages Q3 2024.
ADME industrialization ~90x throughput over manual; genome-scale transcriptomics knockout map; 90% success predicting compound failures.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.